Home › Funds › BENDER ROBERT & ASSOCIATES › URGN

BENDER ROBERT & ASSOCIATES position in URGN

UROGEN PHARMA LTD · Health Care

BENDER ROBERT & ASSOCIATES reported holding 34,701 shares of URGN (UROGEN PHARMA LTD) in its Q3 2026 13F filing — a position valued at US$1.4M, representing 0.27% of its reported portfolio and ranking #27 among its reported holdings. BENDER ROBERT & ASSOCIATES has disclosed URGN holdings in 8 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)34.70K sh
Reported value held$1.41M
Portfolio Weight0.27%
First reportedQ3 2023
Last changeNew
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How BENDER ROBERT & ASSOCIATES's URGN position evolved

BENDER ROBERT & ASSOCIATES first disclosed a stake in URGN in Q3 2023 at 34,701 shares (US$486K). The position peaked in Q3 2026 at 34,701 shares, worth US$1.4M. Across 8 filings, BENDER ROBERT & ASSOCIATES held the position steady without any share-count change. The most recent filing (Q3 2026) shows 34,701 shares valued at US$1.4M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 34.70K $486.16K New
Q4 2023 34.70K $520.51K Hold
Q1 2024 34.70K $520.51K Hold
Q4 2024 34.70K $369.57K New
Q2 2025 34.70K $475.40K New
Q3 2025 34.70K $692.28K Hold
Q1 2026 34.70K $623.92K New
Q3 2026 34.70K $1.41M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About URGN and 13F data

URGN (UROGEN PHARMA LTD) is a Health Care company. 45 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$89.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding URGN

All URGN fund holders →

FAQ

How long has BENDER ROBERT & ASSOCIATES held URGN?

BENDER ROBERT & ASSOCIATES has disclosed URGN holdings in 8 of the last 13 reported quarters, going back to Q3 2023.

What is BENDER ROBERT & ASSOCIATES's current position in URGN?

As of Q3 2026, BENDER ROBERT & ASSOCIATES holds 34.70K shares of URGN (UROGEN PHARMA LTD), valued at $1.41M, representing 0.27% of its reported portfolio and ranking #27.

Has BENDER ROBERT & ASSOCIATES been buying or selling URGN?

In the latest 13F filing (Q3 2026), BENDER ROBERT & ASSOCIATES newly opened its position in URGN. The position peaked in Q3 2026 at 34.70K shares.

Which other funds hold URGN?

Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.